The role of PNPLA3 (rs738409) c>g variant on histological progression of non-alcoholic fatty liver disease
- PMID: 35949720
- PMCID: PMC9349489
- DOI: 10.14744/hf.2020.2020.0023
The role of PNPLA3 (rs738409) c>g variant on histological progression of non-alcoholic fatty liver disease
Abstract
Background and aim: The present study aims to investigate the role of genetic variability of the PNPLA3 gene (adiponectin) in predisposition to non-alcoholic fatty liver disease (NAFLD) by comparing NAFLD patients to healthy controls and to investigate any impact of the PNPLA3 genetic variability on the natural course of the disease.
Materials and methods: This cohort consisted of 174 patients with biopsy-proven NAFLD and 151 healthy controls. DNA was extracted from peripheral blood and the rs738409 C>G single nucleotide polymorphism was assessed using PCR-DNA sequencing.
Results: The frequency distribution of the GG genotype was significantly higher in NAFLD patients than in controls (p=0.01). In patients with NAFLD, the GG genotype was associated with lower platelet counts (p=0.001), the presence of steatohepatitis (p=0.04) and hepatic fibrosis (p=0.016). After adjustment for age, gender, obesity, and diabetes mellitus, the GG genotype was an independent predictor of significant hepatic fibrosis (adjusted odds ratio =3.031 p=0.012). From the baseline to sequential liver biopsies, the progression of NAS in NAFLD patients was slightly higher in the GG genotype than that of CC and GG genotypes (p=0.18).
Conclusion: The PNPLA3 GG genotype is a predisposing factor for the development of hepatic steatosis in NAFLD patients and related to a more severe liver disease.
Keywords: PNPLA3; genome-wide association studies (GWAS); nonalcoholic fatty liver disease; steatohepatitis.
© Copyright 2020 by Hepatology Forum.
Conflict of interest statement
The authors have no conflict of interest to declare.
Figures
Similar articles
-
PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease.World J Hepatol. 2020 Oct 27;12(10):792-806. doi: 10.4254/wjh.v12.i10.792. World J Hepatol. 2020. PMID: 33200017 Free PMC article.
-
PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.Surg Obes Relat Dis. 2015 Jul-Aug;11(4):888-94. doi: 10.1016/j.soard.2014.07.016. Epub 2014 Aug 1. Surg Obes Relat Dis. 2015. PMID: 25240529
-
Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.J Gastroenterol Hepatol. 2020 Jun;35(6):1057-1064. doi: 10.1111/jgh.14894. Epub 2019 Dec 9. J Gastroenterol Hepatol. 2020. PMID: 31677195
-
Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease.Clin Gastroenterol Hepatol. 2023 Dec;21(13):3314-3321.e3. doi: 10.1016/j.cgh.2023.04.024. Epub 2023 May 4. Clin Gastroenterol Hepatol. 2023. PMID: 37149016
-
Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis.BMC Endocr Disord. 2021 Jun 19;21(1):125. doi: 10.1186/s12902-021-00789-4. BMC Endocr Disord. 2021. PMID: 34147109 Free PMC article.
Cited by
-
Genetic Polymorphisms and Diversity in Nonalcoholic Fatty Liver Disease (NAFLD): A Mini Review.Biomedicines. 2022 Dec 30;11(1):106. doi: 10.3390/biomedicines11010106. Biomedicines. 2022. PMID: 36672614 Free PMC article. Review.
-
PNPLA3 rs738409 Genetic Variant Inversely Correlates with Platelet Count, Thereby Affecting the Performance of Noninvasive Scores of Hepatic Fibrosis.Int J Mol Sci. 2023 Oct 10;24(20):15046. doi: 10.3390/ijms242015046. Int J Mol Sci. 2023. PMID: 37894727 Free PMC article.
-
Exposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat.CPT Pharmacometrics Syst Pharmacol. 2025 Feb;14(2):317-330. doi: 10.1002/psp4.13275. Epub 2024 Nov 20. CPT Pharmacometrics Syst Pharmacol. 2025. PMID: 39564924 Free PMC article. Clinical Trial.
-
Lysosomal Acid Lipase Activity in Non-alcoholic Fatty Liver Disease as a Novel Diagnostic and Therapeutic Target: A Systematic Literature Review of Current Evidence and Future Directions.J Clin Exp Hepatol. 2022 Nov-Dec;12(6):1535-1546. doi: 10.1016/j.jceh.2022.04.011. Epub 2022 Apr 15. J Clin Exp Hepatol. 2022. PMID: 36340307 Free PMC article. Review.
-
Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD.Liver Int. 2025 Mar;45(3):e16133. doi: 10.1111/liv.16133. Epub 2024 Oct 16. Liver Int. 2025. PMID: 39412170 Free PMC article. Review.
References
-
- Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis. 2009;13(4):511–531. - PubMed
-
- Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28(4):339–350. - PubMed
-
- Diehl AM, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. N Engl J Med. 2017;377(21):2063–2072. - PubMed
-
- Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020;323(12):1175–1183. - PubMed
-
- Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–1395. - PubMed
LinkOut - more resources
Full Text Sources